EA201790549A1 - Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли - Google Patents

Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли

Info

Publication number
EA201790549A1
EA201790549A1 EA201790549A EA201790549A EA201790549A1 EA 201790549 A1 EA201790549 A1 EA 201790549A1 EA 201790549 A EA201790549 A EA 201790549A EA 201790549 A EA201790549 A EA 201790549A EA 201790549 A1 EA201790549 A1 EA 201790549A1
Authority
EA
Eurasian Patent Office
Prior art keywords
predictive
malignant tumor
biomarkers
individuals
expression
Prior art date
Application number
EA201790549A
Other languages
English (en)
Other versions
EA036671B1 (ru
Inventor
Таша Николль Симс
Бо Гао
Израэль Лови
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201790549A1 publication Critical patent/EA201790549A1/ru
Publication of EA036671B1 publication Critical patent/EA036671B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к способам лечения метастатической злокачественной опухоли, включающим выявление индивидуумов, которые благоприятно ответят на анти-VEGF терапию. По конкретным аспектам изобретения индивидуумов выявляют на основании уровня экспрессии одного или нескольких предиктивных биомаркеров. На благоприятный ответ на анти-VEGF терапию указывают высокие уровни экспрессии определенных биомаркеров или низкие уровни экспрессии определенных биомаркеров. Примером предиктивного биомаркера является VEGF-A. Также в настоящем документе описываются прогностические биомаркеры, полезные для выявления индивидуумов со злокачественной опухолью, у которых ожидаются более лучшие относительные результаты выживаемости.
EA201790549A 2014-09-16 2015-09-10 Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a EA036671B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US201562099630P 2015-01-05 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
EA201790549A1 true EA201790549A1 (ru) 2017-07-31
EA036671B1 EA036671B1 (ru) 2020-12-07

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790549A EA036671B1 (ru) 2014-09-16 2015-09-10 Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a

Country Status (12)

Country Link
US (2) US10525104B2 (ru)
EP (1) EP3194974B1 (ru)
JP (1) JP6692358B2 (ru)
KR (1) KR102471057B1 (ru)
CN (1) CN107076749B (ru)
AU (1) AU2015318207B2 (ru)
CA (1) CA2960890A1 (ru)
EA (1) EA036671B1 (ru)
IL (1) IL250905B (ru)
MX (1) MX2017003387A (ru)
WO (1) WO2016044041A1 (ru)
ZA (1) ZA201701664B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209631A (zh) 2013-03-14 2015-12-30 奥特拉西斯公司 使用所测分析物改进疾病诊断的方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
JP6952056B2 (ja) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
EP3605087B1 (en) * 2017-03-31 2022-09-14 Hirotsu Bio Science Inc. Method for detecting proliferation of cancer in cancer patients
JP2021511061A (ja) 2018-01-26 2021-05-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｖｅｇｆ剤を使用した血管新生障害の治療のための方法および組成物
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
WO2021011491A1 (en) * 2019-07-13 2021-01-21 Otraces Inc. Improving diagnosis for various diseases using tumor microenvironment active proteins
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20220390456A1 (en) * 2019-10-17 2022-12-08 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
KR20140015129A (ko) * 2009-08-14 2014-02-06 알러간, 인코포레이티드 성장 인자 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법
EP2525821A1 (en) * 2010-01-19 2012-11-28 F. Hoffmann-La Roche AG Tumor tissue based biomarkers for bevacizumab combination therapies
WO2012010551A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Also Published As

Publication number Publication date
AU2015318207A1 (en) 2017-04-06
IL250905A0 (en) 2017-04-30
US11439683B2 (en) 2022-09-13
US10525104B2 (en) 2020-01-07
WO2016044041A1 (en) 2016-03-24
US20170281725A1 (en) 2017-10-05
CN107076749B (zh) 2020-12-29
EP3194974B1 (en) 2019-10-23
AU2015318207B2 (en) 2021-11-04
KR102471057B1 (ko) 2022-11-28
JP6692358B2 (ja) 2020-05-13
KR20170055972A (ko) 2017-05-22
IL250905B (en) 2019-12-31
MX2017003387A (es) 2018-01-30
CN107076749A (zh) 2017-08-18
CA2960890A1 (en) 2016-03-24
JP2017530372A (ja) 2017-10-12
ZA201701664B (en) 2018-05-30
EP3194974A1 (en) 2017-07-26
US20200129589A1 (en) 2020-04-30
EA036671B1 (ru) 2020-12-07

Similar Documents

Publication Publication Date Title
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
BR112017020893A2 (pt) método para o tratamento de câncer
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2019028285A3 (en) Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
NZ745327A (en) Whole-cell cancer vaccines and methods for selection thereof
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
EA201890649A1 (ru) Новые биомаркеры и способы лечения рака
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
NZ729773A (en) Biomarkers for disease progression in melanoma
MA40636A (fr) Procédés pour détecter le cancer de la prostate
BR112018009528A2 (pt) método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
BR112016015595A2 (pt) métodos de determinação de câncer de pulmão